News
Purchased mezagitamab royalty and milestone rights held by BioInvent International and will secure royalty economic interests in two early-stage partnered assets through XOMA Royalty’s recently ...
Key Points Revenue (GAAP) beat estimates by 39.5% in Q2 2025, rising to $13.1 million on substantial milestone receipts. Recurring royalty income remained modest, with only $2.6 million from ...
8h
TipRanks on MSNXoma reports Q2 EPS 44c, consensus (15c)
Reports Q2 revenue $13.129M, consensus $9.39M. “We continue to add to our diversified portfolio of both early- and late-stage assets through ...
Turnstone Stockholders Received $0.34 Per Share in Cash Plus Contingent Value Right - EMERYVILLE, Calif., Aug. 11, 2025 ...
Explore XOMA's shift to M&A with CVRs, recent LVTX & HLVX deals, and their potential impact. Learn why analysts maintain a ...
Xoma Royalty kicked off the week by buying up a pair of biotechs that have both struggled to recover from recent clinical ...
Xoma Royalty has agreed to acquire Lava Therapeutics.
XOMA Royalty Corporation and Turnstone Biologics Corp. have announced a merger agreement in which XOMA Royalty will acquire Turnstone for $0.34 in cash per share, along with one non-transferable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results